ARANESP^® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Limitations of Use:

• ARANESP^® has not been shown to improve quality of life, fatigue, or patient well-being.
• ARANESP^® is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia. Close

EPOGEN^® (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney disease (CKD), including patients on dialysis and patients not on dialysis.

Limitations of Use:

• EPOGEN^® has not been shown to improve quality of life, fatigue, or patient well-being.
• EPOGEN^® is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia. Close

Parsabiv^® (etelcalcetide) is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.

Parsabiv^® has not been studied in adult patients with parathyroid carcinoma, primary hyperparathyroidism, or with CKD who are not on hemodialysis and is not recommended for use in these populations.Close